KOPRAN vs SMSPHARMA: Stock Comparison

Kopran Limited vs SMS Pharmaceuticals Limited

Live data: 29 May 2026, 4:01 PM IST • Source: NSE and company filings

SMS Pharmaceuticals Limited is the larger company by market capitalisation. Kopran Limited shows a higher dividend yield, faster revenue growth and lower leverage, while SMS Pharmaceuticals Limited shows a lower P/E, a higher ROE and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Kopran Limited and SMS Pharmaceuticals Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, KOPRAN is more favourable on 5 of 13 scored metrics and SMSPHARMA on 8These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SMSPHARMA is the larger company
₹3,629 Cr vs ₹942 Cr
P/E Ratio
SMSPHARMA has a lower P/E
35.59x vs 38.28x
P/B Ratio
KOPRAN has a lower P/B
1.86x vs 4.62x
EPS
SMSPHARMA has higher earnings per share
₹11.17 vs ₹3.41
Dividend Yield
KOPRAN has a higher dividend yield
1.59% vs 0.1%
Revenue Growth (TTM YoY)
KOPRAN has faster revenue growth
-3.66% vs -4.1%
EPS Growth (TTM YoY)
SMSPHARMA has faster EPS growth
49.2% vs -71.88%
Qtr Sales Growth
KOPRAN has stronger quarterly sales growth
-3.03% vs -4.13%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKOPRANSMSPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKOPRANSMSPHARMA
Live Price₹206.27₹386.85
Day Change6.56%-0.35%
Volume38.55 L1.26 L
52-Week High₹219₹447.8
52-Week Low₹107₹207.99
Distance from 52W High-5.81%-13.61%

Valuation

MetricKOPRANSMSPHARMA
Market Cap₹942 Cr₹3,629 Cr
P/E Ratio38.28x35.59x
P/B Ratio1.86x4.62x
EPS₹3.41₹11.17
Book Value₹107.35₹81.83
Dividend Yield1.59%0.1%

Growth

MetricKOPRANSMSPHARMA
Revenue Growth (TTM YoY)-3.66%-4.1%
EPS Growth (TTM YoY)-71.88%49.2%
Qtr Sales Growth-3.03%-4.13%
Qtr Profit Growth-32.9%61%

Profitability & Leverage

MetricKOPRANSMSPHARMA
ROE4.85%14.3%
ROCE9.75%13.3%
Net Margin3.78%11.5%
Operating Margin6.58%19.3%
Debt to Equity0.29x0.46x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricKOPRANSMSPHARMA
Promoter Holding44.42%68.07%
FII Holding0.51% 0.06 pp0.65% 0.34 pp
DII Holding0%2.83% 0.19 pp
Public Holding55.06% 0.06 pp28.45% 0.15 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Kopran Limited and SMS Pharmaceuticals Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.